Latest news for Tasman Resources (OTC:TASEF) Stock

Tasman Resources Ltd is an Australian exploration company. The company is focusing on exploration projects with the potential to deposit a wide range of precious and base metals including gold, silver, copper, zinc, nickel, and uranium. Its projects are Lake Torrens Project, Pernatty Project and Vulcan prospect. The company's segments include Tasman Resources Ltd and Eden Innovations. It generates maximum revenue from the Eden Innovations segment.

TASMAN RESOURCES NL ORD by Tasman Resources NL

Tasman Resources Ltd

Tasman Resources Ltd (AU:TAS) has released an update. Tasman Resources Ltd has announced the application for quotation of 92,580,323 new ordinary s...

Tasman Resources Readies for New Share Quotation

Tasman Resources Ltd (AU:TAS) has released an update. Tasman Resources Ltd has announced the commencement of a gravity survey at the Parkinson Dam ...

Tasman Resources Advances Exploration with New Survey

Tasman Resources Ltd (AU:TAS) has released an update. Tasman Resources Ltd has confirmed five high-potential drill targets at its Parkinson Dam pro...

Tasman Resources Set for Drilling at Parkinson Dam

Tasman Resources Ltd (AU:TAS) has released an update. Tasman Resources Ltd has released its updated corporate governance statement, detailing its a...

Tasman Resources Updates Corporate Governance Practices

Tasman Resources Ltd (AU:TAS) has released an update. Tasman Resources Ltd has announced a promising development for its Parkinson Dam Project in S...

Tasman Resources Identifies New Drill Targets in Australia

Tasman Resources Ltd (AU:TAS) has released an update. Tasman Resources Ltd announced that all resolutions at their Annual General Meeting, includin...

Tasman Resources Secures Shareholder Support at AGM

Tasman Resources Ltd (AU:TAS) has released an update. Tasman Resources Ltd has outlined its company structure and governance in a newly released co...

Tasman Resources Ltd Details New Corporate Structure

Tasman Resources Ltd (AU:TAS) has released an update. Tasman Resources Ltd has requested a trading halt on its securities due to an inquiry from th...

Tasman Resources Requests Trading Halt Amid ASX Inquiry

Tasman Resources Ltd (AU:TAS) has released an update. Tasman Resources Ltd experienced a significant increase in its share price and trading volume...

Tasman Resources Shares Surge Amid Project Announcement

Tasman Resources Ltd (AU:TAS) has released an update. Tasman Resources Ltd has identified six promising drill targets at its Parkinson Dam gold pro...

Tasman Resources Unveils New Drill Targets at Parkinson Dam

TASEF

Tasman Resources

Transaction Represents Kamada&#39;s Entry into U.S. Plasma Collection Market and Advances the Company&#39;s Strategic Objective to Evolve into a&nbsp;Fully Integrated Specialty Plasma Company 
&nbsp;

Blood and Plasma Research, Inc.&nbsp;Primarily Focuses on Collecting Hyper-Immune Plasma, and Kamada Plans to Significantly Expand its Collection Capacity

REHOVOT, Israel, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:<a class="ticker" href="/stock/KMDA#NASDAQ">KMDA</a>, TASE: KMDA.TA))))), a plasma-derived biopharmaceutical company, today announced that it has entered into an agreement for the acquisition of the plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research, Inc (B&amp;PR) of Beaumont, TX, USA. B&amp;PR&#39;s collection facility primarily specializes in the collection of hyper-immune plasma used for the Anti-D immunoglobulin, which is manufactured by Kamada and distributed in international markets. B&amp;PR&#39;s plasma collection center is one of the few FDA-licensed centers in the U.S. providing the raw materials required for this product.

&quot;The acquisition of this center represents our entry into the U.S. plasma collection market and furthers our strategic goal of becoming a fully integrated specialty plasma company,&quot; said Amir London, CEO of Kamada. &quot;We plan to significantly expand our hyperimmune plasma collection capacity by investing in B&amp;PR&#39;s center at Beaumont, TX, and leveraging its FDA license to open additional centers in the U.S. As demonstrated through the growth of our Anti-Rabies Immunoglobulin (IgG) product in the U.S. and other markets, our increased focus on anti-D sales internationally, and the rapid development and supply of our investigational COVID-19 IgG product, we are committed to growing our hyperimmune IgG portfolio. We believe this acquisition is a significant strategic step in that direction, and it is expected to improve our competitiveness in the different markets. We look forward to successfully growing this emerging business.&quot;

The acquisition for a total consideration of approximately&nbsp;$1.63 million, is expected to be consummated during this quarter, subject to closing conditions as set forth in the acquisition agreement, through Kamada Plasma LLC, a newly formed wholly owned subsidiary of Kamada, which will operate the plasma collection activity in the U.S.

Comments

Tasman Resources

News

Latest news for Tasman Resources (OTC:TASEF) Stock

Monday, February 01, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga